Ilean Lamboy Hernandez
Pulmonary Disease · Ponce, PRNPI 1699123752
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,183 of the $5,322 with a category attached, or 78.6%. 21 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. Reporting peaked in 2024 at $2,555 and has fallen 55.5% since, to $1,137 in 2025.
Across 123 payments — averaging $43.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Inspire Medical Systems, Inc.$1K
- Jazz Pharmaceuticals Inc.$551
- Harmony Biosciences LLC$316
- Bayer$240
- Takeda Pharmaceuticals U.S.A., Inc.$231
- plus $1K from 15 others
What the payments were for
- Travel & lodging$77114%
- Food & beverage$4,18379%
- Education$3687%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $1,499 |
| Inspire Medical Systems, Inc. | 7 | $1,065 |
| Jazz Pharmaceuticals Inc. | 11 | $551 |
| Harmony Biosciences LLC | 5 | $316 |
| Bayer | 2 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $231 |
| GSK | 5 | $209 |
| Mylan Specialty L.p. | 6 | $207 |
| ANI Pharmaceuticals, Inc. | 9 | $178 |
| Merck | 9 | $165 |
| Sanofi | 7 | $157 |
| Boehringer Ingelheim | 1 | $125 |
| Amgen | 4 | $92 |
| Mallinckrodt Hospital Products Inc. | 1 | $66 |
| Johnson & Johnson | 3 | $66 |
| Viatris Specialty LLC | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| PBG Puerto Rico LLC | 1 | $26 |
| Medtronic | 1 | $22 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $19 |
| United Therapeutics Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,322 in reported general payments places this provider in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 28 | $386,756 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $20,212 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,796 |
| Wixela InhubFluticasone Propion/Salmeterol | 44 | $9,639 |
| Atrovent HfaIpratropium Bromide | 15 | $7,140 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $5,254 |
| Fluticasone Propionate | 61 | $1,478 |
| Montelukast Sodium | 109 | $918 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 12 | $690 |
| Famotidine | 103 | $634 |
| Pantoprazole Sodium | 35 | $263 |
| Dexamethasone | 15 | $225 |
| Omeprazole | 16 | $87 |
| Prednisone | 14 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $240 | $386,75628 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $209 | $32,00851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Ponce
- Domingo Chardon FelicianoPonce$45K
- George FahedPonce$16K
- Giovanni Veloz IrizarryPonce$11K
- Dev Boodoosingh CasianoPonce$10K
- Jesse Aleman-OrtizPonce$10K
- Keren Mendez RamirezPonce$8K
- Hector Puig-RamirezPonce$8K
- Sandra Galarza-VargasPonce$7K
- Eugenio Rivera RiosPonce$3K
- Manuel Morell CataquetPonce$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.